Loading…
Dongguan drugmaker of anti-infective and chronic-disease medicines, best known for the Kewei oseltamivir flu drug; HEC Group affiliate.
Dongguan drugmaker of anti-infective and chronic-disease medicines, best known for the Kewei oseltamivir flu drug; HEC Group affiliate.
Develops and makes its own drugs and sells them to Chinese hospitals and pharmacies, so a few products carry the business, above all the Kewei flu medicine, whose sales rise and fall with flu seasons. It is vertically integrated, tied to the HEC Group of Dongguan, and listed in Hong Kong in 2025.
Moat: narrow (IP / patents, regulatory licence). Exclusive patented Kewei granule form and drug approvals, but flu-season dependence and China's volume-based procurement pricing limit it.
Headquarters: Dongguan, China · Employees: 6,353
Size Sunshine Lake Pharma (6887.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $2.85B, the 348th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$38.80 on 6 Nov 2026.
Performance Over six months the shares fell 9.1%, against -5.8% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 20.2% over the last twelve months (peer median +3.9%); the operating margin is -2.6% (peer median -25.4%).
Valuation It trades at 6.1× enterprise value to sales against a peer median of 13.7× (7th cheapest of 19).
Capital Return on invested capital runs 6.2 points below its cost of capital (5.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$4.38B | HK$5.22B | HK$4.36B | HK$7.06B | HK$4.43B |
| Revenue growth | — | +20% | -38% | +59% | — |
| Gross profit | HK$3.09B | HK$4.00B | HK$3.15B | HK$5.50B | HK$3.15B |
| EBITDA | HK$420M | HK$1.08B | HK$769M | HK$2.88B | HK$1.05B |
| Net income | -HK$339M | HK$295M | -HK$225M | HK$204M | -HK$1.41B |
| Free cash flow | -HK$109M | HK$147M | -HK$659M | HK$846M | HK$298M |
| Capital expenditure | HK$314M | HK$1.01B | HK$1.33B | HK$591M | HK$1.18B |
| Total debt | n/a | HK$5.35B | HK$5.49B | HK$6.12B | HK$7.35B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Sunshine Lake Pharma 6887.HK | $2.85B | -9% | +20% | -3% | 6.1× | n/a |
| Cspc Pharma 1093.HK | $12.4B | +5% | +25% | 28% | 2.2× | -10.3% |
| Hansoh Pharma 3692.HK | $26.9B | -7% | +25% | 38% | 9.7× | 8.9% |
| Simcere Pharmaceutical 2096.HK | $3.63B | -7% | +27% | 18% | 2.7× | -2.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6887.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.6% | -7.3% | 10th highest of 21 |
| 6-month return | -9.1% | -5.8% | 10th lowest of 20 |
| Distance from 52-week high | -24.9% | -30.1% | 7th highest of 21 |
| Revenue growth (TTM) | +20.2% | +3.9% | 6th highest of 18 |
| Operating margin | -2.6% | -25.4% | 9th highest of 18 |
| EV / Sales | 6.1× | 13.7× | 7th cheapest of 19 |
| ROIC minus cost of capital | -6.2 pp | -9.4 pp | 8th highest of 16 |
| EV / EBITDA | 64.0× | 36.3× | most expensive of 5 |
| Net debt / EBITDA | 10.7× | 0.3× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | 6.1× | n/a | n/a |
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 5.7× | -0.8% | +64.6% |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 14.2× | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | 5.5× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 2.8× | -2.0% | +27.4% |
| Xeris Biopharma XERS | United States | $2.77B | +133% | +36% | 11% | 8.8× | 33.3% | +70.2% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.76B | -23% | +18% | 27% | 4.7× | 0.5% | +36.0% |
| Beam Therapeutics BEAM | United States | $2.73B | -18% | +163% | -268% | 13.2× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.71B | -12% | -23% | 5% | 10.3× | 31.3% | -3.8% |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | 6,237.3× | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.68B | -52% | 0% | -25% | 21.9× | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | 45.9× | n/a | n/a |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | 22.6× | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | 17.1× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.58B | n/a | n/a | n/a | 67.9× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | 128.0× | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 3.9× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | 26.3× | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.37B | -15% | -11% | 17% | 5.6× | 16.7% | -1.8% |